期刊
SEMINARS IN ARTHRITIS AND RHEUMATISM
卷 51, 期 4, 页码 880-887出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semarthrit.2021.06.006
关键词
Psoriatic arthritis; Spondyloarthropathies; Inflammatory arthritis; Inflammatory back pain
类别
资金
- Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Psoriatic arthritis (PsA) is a chronic, inflammatory musculoskeletal disease with heterogeneous characteristics, and axial involvement can lead to complications in management and treatment decisions. The lack of agreed-upon classification and diagnostic criteria for axial PsA complicates the approach to this subset of patients.
Psoriatic arthritis (PsA) is a heterogenous, chronic, inflammatory musculoskeletal disease that can lead to peripheral and axial damage and loss of function. Axial involvement occurs in 25% to 70% of patients with PsA, varying greatly depending on its definition, with the key manifestations being sacroiliitis and/or spondylitis. However, there are no agreed-upon classification or diagnostic criteria for axial involvement in PsA and no consensus on treatment paradigms, which complicates management of PsA. There have only been a few studies assessing biologics in patients with PsA with axial involvement, and most treatment plans are based on evidence from patients with axial spondyloarthritis. Rheumatologists therefore face many challenges in the management of axial PsA, including diagnosis, differential diagnosis, and choice of appropriate treatment. In this review, we summarize the clinical presentation, imaging characteristics, differential diagnoses, treatment options, and prognosis of axial PsA, with the aim of increasing rheumatologists' knowledge of this phenotype of PsA and thereby aiding its optimal management . (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据